BioTuesdays

Category - Markets

IRIDEX

Roth starts IRIDEX at buy

Roth Capital Partners initiated coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and $20 price target. The stock closed at $13.22 on Dec. 20. Iridex is an ophthalmic medical device company focused on development and...

Cidara Therapeutics Logo

HCW starts Cidara Therapeutics at buy

H.C. Wainwright launched coverage of Cidara Therapeutics (NASDAQ:CDTX) with a “buy” rating and $25 price target. The stock closed at $10.80 on Dec. 16. Cidara’s lead drug, CD101 IV, is a novel molecule in the...

Histogenics

HCW starts Histogenics at buy

H.C. Wainwright initiated coverage of Histogenics (NASDAQ:HSGX) with a “buy” rating and price target of $3.50, saying the company has an innovative product with significant market potential. The stock closed at $1.58 on...

Organovo Holdings

BTIG starts Organovo at buy

BTIG initiated coverage of Organovo Holdings (NASDAQ:ONVO) with a “buy” rating and $5 price target. The stock closed at $3.69 on Dec. 14. Organovo uses 3D printing and “bio-ink” to create 3D tissue structures without...

atyr Pharma

WB cuts price target for aTyr Pharma to $4

William Blair slashed its price target for aTyr Pharma (NASDAQ:LIFE) to $4 from $8 but maintained its “market perform” rating after the company released data from three Phase 1/2 studies of Resolaris in rare muscle...

Dicerna Logo

HCW starts Dicerna at buy

H.C. Wainwright initiated coverage of Dicerna Pharmaceuticals (NASDAQ:DRNA) with a “buy” rating and $7 price target. The stock closed at $3.05 on Dec. 12. Dicerna recently announced its intention to shift development of...

Nobilis Health

Craig-Hallum downgrades Nobilis to hold

Craig-Hallum downgraded Nobilis Health (NASDAQ:HLTH) to “hold” from “buy” and slashed its price target to $2 from $6. The stock closed at $2.25 on Dec. 12. Analyst Charles Haff attributed the downgraded to what he...

Concordia International

RBC downgrades Concordia Intl to underperform

RBC Capital Markets downgraded Concordia International (NASDAQ:CXRX; TSX:CXR) to “underperform” from “sector perform” and cut its price target to $1 from $2.50. The stock closed at $2.38 on Dec. 6. Britain’s Competition...

iRhythm Technologies

BTIG downgrades iRhythm to neutral

BTIG downgraded iRhythm Technologies (NASDAQ:IRTC) to “neutral” from “buy,” noting that the shares recently surpassed BTIG’s price target of $28 but have fallen $1.25 at midday Dec.6 to $27.98. “We are not making...

Neovasc Logo

Echelon ups Neovasc price target to $3.25

Echelon Wealth Partners raised its price target for Neovasc (NASDAQ:NVCN) to $3.25 from $1.25 after the company sold its PeriPatch processing operations to Boston Scientific (NYSE:BSX). The stock closed at 86 cents on...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.